BioSpace

Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor

Merck continues to diversify its cancer efforts as the clock ticks down on Keytruda’s patent, picking up rights to a preclinical oncology asset in a deal that could exceed $2 billion.

作者 BioSpace

1 分钟阅读
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Health Tech相关内容

相关洞察